Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny, a leading fertility benefits management company, announced that CEO David Schlanger will present at the 39th Annual JP Morgan Healthcare Conference on January 12, 2021, at 3:40 P.M. Eastern Time. Following the presentation, President and COO Pete Anevski and CFO Mark Livingston will join Schlanger for a breakout session. A live audiocast and replay will be available on Progyny's website. The company is dedicated to redefining fertility benefits, providing comprehensive solutions that benefit employers, patients, and healthcare providers.
Progyny (Nasdaq: PGNY) has announced the addition of two new board members: Malissia R. Clinton and Roger Holstein, effective November 16, 2020. Clinton, with over 25 years in various industries, will serve on the Nominating and Governance Committee, while Holstein, a healthcare industry veteran, will join the Compensation Committee. Their expertise in healthcare and technology aims to provide strategic guidance as Progyny transitions to a high-growth leader in fertility benefits management. The board now consists of nine directors, enhancing the company's governance and industry insights.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced that CEO David Schlanger will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The pre-recorded chat will be accessible from November 23 on Progyny’s website. Additionally, the company will conduct one-on-one meetings on December 1, with requests made exclusively through Piper Sandler. Progyny's innovative benefits solution aims to redefine fertility support, offering education, access to specialists, and improved clinical outcomes while reducing costs for employers.
Progyny, a leader in fertility benefits management, reported third quarter 2020 revenue of $98.9 million, up 62% from prior year. Net income hit $5.4 million, reversing an $8.2 million loss year-over-year. The company anticipates 2020 revenue guidance of $340-$345 million, targeting a growth of 48%-50%. For 2021, Progyny projects a minimum of $525 million in revenue with 180 clients covering 2.7 million lives. Adjusted EBITDA nearly doubled to $10.6 million, demonstrating strong operational leverage despite COVID-19.
Progyny, a leader in fertility benefits management, is scheduled to report its financial results for Q3 2020 on Nov. 5, 2020, after market close. A conference call will follow at 4:45 PM ET, accessible via specific dialing numbers for U.S. and international participants. An audio replay will be available until Nov. 12, 2020. Progyny is recognized for its innovative fertility solutions, enhancing access for patients while reducing healthcare costs for employers. With headquarters in New York, the company is gaining attention for its impact on fertility benefits.
Progyny (Nasdaq: PGNY) presented research at the ASRM Scientific Congress on October 17, 2020, focusing on factors influencing patient progression to infertility treatment. Analyzing 8,441 cases from 600 clinics with employer-sponsored coverage, key findings revealed that increased interactions with patient care advocates significantly boost treatment progression rates from 72% to 82%. Patients aged 35-38 were most likely to progress, while those with male infertility diagnoses showed lower progression rates. The study aims to enhance understanding of barriers patients face even when financial hurdles are addressed.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced the participation of its CEO, David Schlanger, in a fireside chat at the BofA Global Healthcare Conference on September 17, 2020, at 11:45 A.M. ET. This event highlights the company's commitment to redefining fertility and family-building benefits. Progyny aims to empower patients through dedicated advocacy, access to specialists, and cost reduction for employers. The event will be audiocasted live and available for replay on Progyny's website.
Progyny (Nasdaq: PGNY) has appointed Mark Livingston as Chief Financial Officer, effective September 15, 2020. He brings over 30 years of experience, having previously served as CFO at Scripps Network Interactive and Emerson, Reid & Company. Livingston's promotion allows President Pete Anevski to focus more on business growth, as Progyny addresses significant market opportunities in fertility benefits management. The company aims to enhance patient outcomes and reduce costs for employers while expanding its leadership position in the market.
Progyny reported Q2 revenue of $64.6 million, marking a 15% increase from $56.2 million in 2019. Patient activity recovered faster than expected, with fertility treatment volumes improving as clinics reopened. For full-year 2020, revenue guidance is set between $323 million and $340 million, indicating growth of 41% to 48%. Q3 revenue is projected at $88 million to $95 million. However, the company noted a net loss of $1.8 million due to operational costs amid pandemic disruptions. Adjusted EBITDA was $3 million, reflecting resilience despite challenges.
Progyny (Nasdaq: PGNY) will announce its financial results for the quarter ending June 30, 2020, on August 5, 2020. The report will be released after market close, followed by a conference call at 4:45 PM ET.
Participants can access the call by dialing specific numbers for U.S. and international attendees. An audio replay will be available until August 11, 2020. Progyny, a leader in fertility benefits management, emphasizes a comprehensive approach that supports employers and patients alike.